TAXUS PHARMACEUTICALS HOLDINGS, INC.
CIK:0001622676|SEC Filings
Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2018 |
Mar. 31, 2017 |
Mar. 31, 2018 |
Mar. 31, 2017 |
|
| Income Statement [Abstract] | ||||
| Revenues | $ 500 | $ 5,851 | ||
| Cost of revenues | 4,389 | |||
| Gross profit | 500 | 1,462 | ||
| Operating expenses: | ||||
| Selling, general and administration expenses | 3,000 | 11,885 | 19,020 | 85,557 |
| Net (loss) | $ (3,000) | $ (11,885) | $ (18,520) | $ (84,095) |
| (Loss) per common share, basic and diluted | $ (0.00) | $ (0.00) | $ (0.00) | $ (0.00) |
| Weighted average shares outstanding, Basic and diluted | 81,500,200 | 81,500,200 | 81,500,200 | 81,500,200 |
Statements of Cash Flows (Unaudited) - USD ($) |
9 Months Ended | |
|---|---|---|
Mar. 31, 2018 |
Mar. 31, 2017 |
|
| Cash flows from operating activities: | ||
| Net (loss) | $ (18,520) | $ (84,095) |
| Adjustment to reconcile net (loss) to net cash (used in) operating activities | ||
| Inventory obsolescence | 20,763 | |
| Change in operating assets and liabilities: | ||
| Decrease in inventory | 3,394 | |
| Decrease in security deposit | 3,000 | 7,488 |
| (Decrease) increase in accounts payable and accrued expenses | (39,964) | 15,099 |
| Net cash (used in) operating activities | (55,484) | (37,351) |
| Cash flows from financing activities: | ||
| Capital contribution from shareholder | 55,464 | 14,000 |
| Net cash provided by financing activities | 55,464 | 14,000 |
| Net change in cash | (20) | (23,351) |
| Cash, beginning of the period | 5,856 | 29,310 |
| Cash, end of the period | 5,836 | 5,959 |
| Cash paid during the period for: | ||
| Income taxes | ||
| Interest | ||
Balance Sheets - USD ($) |
Mar. 31, 2018 |
Jun. 30, 2017 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 5,836 | $ 5,856 |
| Total current assets | 5,836 | 5,856 |
| Other assets: | ||
| Security deposit | 3,000 | |
| TOTAL ASSETS | 5,836 | 8,856 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 22,551 | 62,515 |
| Total current liabilities | 22,551 | 62,515 |
| Commitments and contingencies | ||
| Stockholders' (deficit): | ||
| Common stock, $0.00001 par value per share; 1,500,000,000 shares authorized; 81,500,200 shares issued and outstanding as of March 31, 2018 and June 30, 2017 | 815 | 815 |
| Additional paid-in capital | 704,365 | 648,901 |
| (Deficit) | (721,895) | (703,375) |
| Total stockholders' (deficit) | (16,715) | (53,659) |
| TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) | $ 5,836 | $ 8,856 |